Aerska
Aerska uses a proprietary brain shuttle technology to deliver RNAi drugs to the central nervous system, opening a new therapeutic route for rare and degenerative neurological diseases.
Europe's most interesting startup stories. Every week.
No spam. Unsubscribe anytime.
Podcast Episode
🎙️ Deep Dive
Daily News – 10 February 2026
Listen to the episodeAbout Aerska
Aerska is an Irish biotech startup that emerged from stealth in October 2025, headquartered in Dublin with research operations in London. The company has developed an RNA platform with brain shuttle technology capable of delivering RNAi drugs across the blood-brain barrier to silence genes involved in neurodegenerative diseases. After a $21M seed, in February 2026 it closed a $39M Series A led by EQT Dementia Fund and Age1, bringing total raised to $60M.
Market & Clients
Key Customers
Researchers and clinicians in rare and degenerative neurological diseases.
Geographic Presence
Funding & Investors
Funding Rounds
- 2026 - Series A: €32M
Key Investors
Similar Startups
LetsGetChecked
At-home diagnostics platform enabling users to order medical test kits and receive professional medical consultations for preventive health monitoring.
Read AnalysisWebDoctor
WebDoctor is an Irish telemedicine service founded in 2015 in Dublin that enables online medical consultations via video call. Through the website or app, patients can speak with registered doctors and receive digital diagnoses and prescriptions without visiting a clinic. It partners with health insurers to facilitate access to primary care online.
Read AnalysisKry
Digital health platform offering telemedicine and online doctor consultations for Nordic and European users.
Read Analysis